Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Department of Internal Medicine, Aichi Prefectural Hospital, Okazaki, Aichi, Japan.
J Chemother. 2024 Apr;36(2):127-132. doi: 10.1080/1120009X.2023.2289268. Epub 2023 Dec 3.
Remdesivir is an antiviral drug for the treatment of coronavirus disease 2019 (COVID-19), and the sustained antiviral activity against Omicron variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been reported. In this single-center retrospective study, we first compared the clinical effectiveness of remdesivir-based therapy between Omicron and other variant phases of moderate COVID-19 in a real-world setting. Between Dec 2020 and July 2022, a total of 406 patients with COVID-19 pneumonia were treated with remdesivir-based therapy on admission. The oxygen deterioration rate after initiation of treatment significantly decreased in the Omicron variant phase compared to the alpha and delta variant phases. In an adjusted multivariate Cox proportional hazards model, Omicron variant phase was significantly associated with delayed oxygen deterioration and early recovery from hypoxia. These favorable outcomes during the Omicron variant phase, compared to previous variant phases, might be due to the attenuation and the popularization of vaccination.
瑞德西韦是一种用于治疗 2019 年冠状病毒病（COVID-19）的抗病毒药物，据报道其对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的奥密克戎变体具有持续的抗病毒活性。在这项单中心回顾性研究中，我们首先在真实环境中比较了奥密克戎变体与其他中度 COVID-19 变体阶段使用瑞德西韦治疗的临床效果。2020 年 12 月至 2022 年 7 月，共有 406 例 COVID-19 肺炎患者在入院时接受了基于瑞德西韦的治疗。与阿尔法和德尔塔变体阶段相比，治疗开始后氧气恶化率在奥密克戎变体阶段显著降低。在调整后的多变量 Cox 比例风险模型中，奥密克戎变体阶段与缺氧延迟恶化和早期恢复显著相关。与之前的变体阶段相比，奥密克戎变体阶段出现这些有利的结果可能归因于疫苗的衰减和普及。
